P1/2, N=47, Completed, Sen-Jam Pharmaceutical

P3, N=4633, Terminated, University of Southampton | N=25210 --> 4633 | Recruiting --> Terminated; Planned recruitment total was not achievable within the funded timeframe

P3, N=2514, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Feb 2026

P1/2, N=30, Completed, UZ Leuven | Recruiting --> Completed

P2, N=46, Completed, Cumberland Pharmaceuticals | Active, not recruiting --> Completed

Co-administration of ASA markedly mitigated these biochemical and histopathological alterations, normalizing antioxidant defenses and downregulating inflammatory mediators and NF-κB activation. The obtained results suggest that ASA is not toxic in this context and may actually protect against the liver and brain damage caused by IMID by dampening the oxidative stress and inflammatory responses driven by HMGB1 and NF-κB.

The prognostic significance was also revealed for preoperative N-terminal prohormone of brain natriuretic peptide (HR 1.18, 95% CI 1.03-1.34, P=0.014), advanced cancer stage (HR 3.21, 95% CI 1.28-8.04, P=0.013), adjuvant chemotherapy (HR 0.22, 95% CI 0.08-0.57, P=0.002), and aspirin use (HR 0.09, 95% CI 0.01-0.72, P=0.024). Myocardial injury within the first 72 hours after surgical lung resection was found as an independent predictor of 1-year all-cause mortality in patients with NSCLC.

P2/3, N=40, Not yet recruiting, Aft Pharmaceuticals Limited

Improving adherence and endoscopic quality, considering adjunctive techniques (eg, faecal immunochemical testing between surveillance intervals, chromoendoscopy/AI (artificial intelligence) assistance), and exploring complementary strategies (eg, aspirin chemoprevention, biomarker-guided risk) are priorities. This narrative review synthesises current evidence, highlighting the need for robust future studies to optimise patient surveillance.

The molecular scaffold of ISSM is constructed by conjugating the cyclooxygenase-2 (COX-2) inhibitor indomethacin with an ER-targeting moiety via a disulfide-containing linker...Here, ISSM simultaneously regulates the defence and execution systems of ferroptosis, leading to robust lipid peroxidation and potent ferroptotic cell death. This work elucidates an ER-targeting nanotherapeutic strategy that specifically amplifies ferroptosis by concurrently depleting glutathione and elevating AA levels, offering a compelling approach for cancer therapy.

While arsenic trioxide (As(III)) demonstrates therapeutic potential through ferroptosis induction, its clinical application is severely constrained by dose-limiting systemic toxicity and consequent inflammation-mediated COX2/PGE2 pathway activation, which confers ferroptosis resistance...TCADS comprises two rationally designed self-assembling peptides incorporating As(III)-binding domains, tumor-selective targeting moieties (MMP9-responsive and Tenascin C-targeting motifs), and the COX2 antagonist naproxen (NPX)...This precision-targeted approach empowers TCADS to effectively disrupt the deleterious inflammation-ferroptosis resistance cycle, thereby successfully overcoming treatment resistance and suppressing tumor progression by 85.0% and 95.4% in subcutaneous and orthotopic tumor models, respectively. This integrated paradigm of precision-targeted delivery coupled with microenvironment modulation establishes a compelling therapeutic framework for chemoresistant HR-NB and potentially other MYCN-amplified malignancies.

P2, N=5478, Recruiting, University of Miami | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027